NEW YORK, May 16 – Merck’s acquisition of Rosetta Inpharmatics will not affect the alliance between Rosetta and Agilent Technologies, an exclusive distributor of the Rosetta Resolver gene expression system, Merck and Agilent said Wednesday.
Following Merck’s acquisition of Rosetta, Agilent will continue to work with Rosetta as the only outside distributor of Rosetta Resolver, and will continue to work with Rosetta to develop gene expression technologies.
"Merck is enthusiastic about the tools developed by Rosetta and our interaction with Agilent," Bennett Shapiro, executive vice president of worldwide licensing and external research at Merck Research Laboratories, said in a statement.
"Our company will continue the activities related to the Rosetta Resolver business and the key inkjet array technology. Moreover, we look forward to obtaining DNA microarrays from Agilent and utilizing such technologies for drug discovery."
Rosetta is a major purchaser of Agilent DNA microarrays.
Following completion of the acquisition, Rosetta will be run as a wholly owned Merck subsidiary and will continue to operate under the name Rosetta Inpharmatics.
Separately, Agilent also announced that it was launching a human cDNA microarray kit, which contains Incyte’s Human UniGene 1 and Human Drug Target clone sets. Agilent said the new product would be the first in a number of microarray products the company would launch this year.